The value of immunohistochemistry for CD14, CD123, CD33, myeloperoxidase and CD68R in the diagnosis of acute and chronic myelomonocytic leukaemias

Histopathology

Volumn 60, Issue 6, 2012, Pages 933-942

  Rollins Raval, Marian A ^a   Roth, Christine G ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Acute myeloid leukaemia with monocytic differentiation; Bone marrow biopsy; CD123 and CD33 immunohistochemistry; CD14; Chronic myelomonocytic leukaemia

Indexed keywords

CD123 ANTIGEN; CD133 ANTIGEN; CD14 ANTIGEN; CD68 ANTIGEN; MYELOPEROXIDASE;

ACUTE MYELOMONOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ANTIBODY LABELING; ARTICLE; BONE MARROW BIOPSY; CANCER CLASSIFICATION; CANCER DIAGNOSIS; CELL DIFFERENTIATION; CHRONIC MYELOMONOCYTIC LEUKEMIA; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD; ANTIGENS, CD14; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; CHILD; CHILD, PRESCHOOL; HUMANS; IMMUNOHISTOCHEMISTRY; INFANT; INTERLEUKIN-3 RECEPTOR ALPHA SUBUNIT; LEUKEMIA, MYELOMONOCYTIC, ACUTE; LEUKEMIA, MYELOMONOCYTIC, CHRONIC; MIDDLE AGED; PEROXIDASE; RETROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84860308669     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2012.04175.x     Document Type: Article

References (31)

1. Swerdlow S, Campo E, Harris N et al. eds. World Health Organization classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press, 2008.
2. Goasguen JE, Bennett JM, Bain BJ, Vallespi T, Brunning R, Mufti GJ. Morphological evaluation of monocytes and their precursors. Haematologica 2009; 94; 994-997.
3. Naresh KN. Morphological evaluation of monocytes and monocyte precursors in bone marrow trephine biopsies-need for establishing diagnostic criteria. Haematologica 2009; 94; 1623-1624.
4. Manaloor EJ, Neiman RS, Heilman DK et al. Immunohistochemistry can be used to subtype acute myeloid leukemia in routinely processed bone marrow biopsy specimens. Comparison with flow cytometry. Am. J. Clin. Pathol. 2000; 113; 814-822.
5. Orazi A, Chiu R, O'Malley DP et al. Chronic myelomonocytic leukemia: the role of bone marrow biopsy immunohistology. Mod. Pathol. 2006; 19; 1536-1545.
6. Xu Y, McKenna RW, Wilson KS, Karandikar NJ, Schultz RA, Kroft SH. Immunophenotypic identification of acute myeloid leukemia with monocytic differentiation. Leukemia 2006; 20; 1321-1324.
7. Dunphy CH, Orton SO, Mantell J. Relative contributions of enzyme cytochemistry and flow cytometric immunophenotyping to the evaluation of acute myeloid leukemias with a monocytic component and of flow cytometric immunophenotyping to the evaluation of absolute monocytoses. Am. J. Clin. Pathol. 2004; 122; 865-874.
8. Yang DT, Greenwood JH, Hartung L, Hill S, Perkins SL, Bahler DW. Flow cytometric analysis of different CD14 epitopes can help identify immature monocytic populations. Am. J. Clin. Pathol. 2005; 124; 930-936.
9. Cibull TL, Thomas AB, O'Malley DP, Billings SD. Myeloid leukemia cutis: a histologic and immunohistochemical review. J. Cutan. Pathol. 2008; 35; 180-185.
10. Hoyer JD, Grogg KL, Hanson CA, Gamez JD, Dogan A. CD33 detection by immunohistochemistry in paraffin-embedded tissues: a new antibody shows excellent specificity and sensitivity for cells of myelomonocytic lineage. Am. J. Clin. Pathol. 2008; 129; 316-323.
11. Xu Y, McKenna RW, Karandikar NJ, Pildain AJ, Kroft SH. Flow cytometric analysis of monocytes as a tool for distinguishing chronic myelomonocytic leukemia from reactive monocytosis. Am. J. Clin. Pathol. 2005; 124; 799-806.
12. Civin CI. Human monomyeloid cell membrane antigens. Exp. Hematol. 1990; 18; 461-467.
13. Qubaja M, Marmey B, Le Tourneau A et al. The detection of CD14 and CD16 in paraffin-embedded bone marrow biopsies is useful for the diagnosis of chronic myelomonocytic leukemia. Virchows Arch. 2009; 454; 411-419.
14. Du X, Ho M, Pastan I. New immunotoxins targeting CD123, a stem cell antigen on acute myeloid leukemia cells. J. Immunother. 2007; 30; 607-613.
15. Djokic M, Bjorklund E, Blennow E, Mazur J, Soderhall S, Porwit A. Overexpression of CD123 correlates with the hyperdiploid genotype in acute lymphoblastic leukemia. Haematologica 2009; 94; 1016-1019.
16. Arber DA, Brunning RD, Orazi A et al. Acute myeloid leukemia, not otherwise specified. in Swerdlow SH, Campo E, Harris NL et al. eds. World Health Organization classification of tumours of haematopoietic and lymphoid tissues, 4th edn. Lyon: IARC Press, 2008; 130-139.
17. Jilani I, Estey E, Huh Y et al. Differences in CD33 intensity between various myeloid neoplasms. Am. J. Clin. Pathol. 2002; 118; 560-566.
18. Tallman MS, Kim HT, Paietta E et al. Acute monocytic leukemia (French-American-British classification M5) does not have a worse prognosis than other subtypes of acute myeloid leukemia: a report from the Eastern Cooperative Oncology Group. J. Clin. Oncol. 2004; 22; 1276-1286.
19. Valk PJ, Verhaak RG, Beijen MA et al. Prognostically useful gene-expression profiles in acute myeloid leukemia. N. Engl. J. Med. 2004; 350; 1617-1628.
20. Wilson CS, Davidson GS, Martin SB et al. Gene expression profiling of adult acute myeloid leukemia identifies novel biologic clusters for risk classification and outcome prediction. Blood 2006; 108; 685-696.
21. Oki Y, Jelinek J, Beran M, Verstovsek S, Kantarjian HM, Issa JP. Mutations and promoter methylation status of NPM1 in myeloproliferative disorders. Haematologica 2006; 91; 1147-1148.
22. Caudill JS, Sternberg AJ, Li CY, Tefferi A, Lasho TL, Steensma DP. C-terminal nucleophosmin mutations are uncommon in chronic myeloid disorders. Br. J. Haematol. 2006; 133; 638-641.
23. Bains A, Luthra R, Medeiros LJ, Zuo Z. FLT3 and NPM1 mutations in myelodysplastic syndromes: frequency and potential value for predicting progression to acute myeloid leukemia. Am. J. Clin. Pathol. 2011; 135; 62-69.
24. Ngo N, Lampert IA, Naresh KN. Bone marrow trephine findings in acute myeloid leukaemia with multilineage dysplasia. Br. J. Haematol. 2008; 140; 279-286.
25. Dunphy CH. Comparative analysis of detecting monocytic cells and their aberrancy. Appl. Immunohistochem. Mol. Morphol. 2011; 19; 336-340.
26. Riccioni R, Diverio D, Riti V et al. Interleukin (IL)-3/granulocyte macrophage-colony stimulating factor/IL-5 receptor alpha and beta chains are preferentially expressed in acute myeloid leukaemias with mutated FMS-related tyrosine kinase 3 receptor. Br. J. Haematol. 2009; 144; 376-387.
27. Chen YC, Chou JM, Ketterling RP, Letendre L, Li CY. Histologic and immunohistochemical study of bone marrow monocytic nodules in 21 cases with myelodysplasia. Am. J. Clin. Pathol. 2003; 120; 874-881.
28. Vermi W, Facchetti F, Rosati S et al. Nodal and extranodal tumor-forming accumulation of plasmacytoid monocytes/interferon-producing cells associated with myeloid disorders. Am. J. Surg. Pathol. 2004; 28; 585-595.
29. Mohty M, Jarrossay D, Lafage-Pochitaloff M et al. Circulating blood dendritic cells from myeloid leukemia patients display quantitative and cytogenetic abnormalities as well as functional impairment. Blood 2001; 98; 3750-3756.
30. Jegalian AG, Facchetti F, Jaffe ES. Plasmacytoid dendritic cells: physiologic roles and pathologic states. Adv. Anat. Pathol. 2009; 16; 392-404.
31. Bovio IM, Allan RW. The expression of myeloid antigens CD13 and/or CD33 is a marker of ALK+ anaplastic large cell lymphomas. Am. J. Clin. Pathol. 2008; 130; 628-634.